Drug Profile

YOLT 101

Alternative Names: YOLT-101

Latest Information Update: 16 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator YolTech Therapeutics
Class Antihyperlipidaemics; Gene therapies
Mechanism of Action Gene transference; PCSK9 protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase 0 Hyperlipoproteinaemia type IIa

Most Recent Events

06 Jun 2025 US FDA clears IND application for YOLT 101 in Hyperlipoproteinaemia-type-IIa
28 Apr 2025 Interim adverse events, pharmacodynamics and efficacy data from a phase-0 trial in Hyperlipoproteinaemia type IIa released by YolTech Therapeutics
26 Mar 2025 Updated efficacy and adverse events from a phase 0 trial in Hyperlipoproteinaemia type IIa released by YolTech Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com